论文部分内容阅读
在做投资之前,我从事新药研发大概有20年。就我个人观点,中国大医疗健康产业最缺同时也最有机会的是新药和医疗服务。具体来讲,创新药、高端生物仿制药和医疗卫生系统改革是我在2013年最关注的领域和方向。欧美真正有实力的医疗公司,都是以研发创新药为主。一个市场很小的药拿到新药证书就值十几亿美元,市场大的药收益可达上百亿美元。从投入、回报的比例来看是值得的,一些针对疑难疾病的新药往往能在很长一段时间内依靠专利保护雄霸市场。
Before investing, I was engaged in research and development of new drugs for about 20 years. From my personal point of view, the greatest shortage of medical care and health industries in China is the new drug and medical service. Specifically, innovations, high-end biosimilars, and health care system reforms are the fields and directions that I focus most on in 2013. The truly powerful medical companies in Europe and the United States use R&D and innovation drugs. A drug with a small market price is worth more than a billion dollars for a new drug certificate, and the market’s large drug profits can reach hundreds of billions of dollars. From the perspective of the ratio of investment and return, it is worthwhile, some new drugs for difficult diseases can often rely on patent protection to dominate the market for a long period of time.